# Calycosin Inhibits Pancreatic Cancer Cell Proliferation, Migration and Invasion by Repressing Circ\_0000285

RUIBING MA, XIAOPING YU AND KUN CHENG1\*

Characteristic Specialty One Group Department, Xinjiang Municipal Corps Hospital Chinese People's Armed Police Force (CAPF), <sup>1</sup>Department of Pancreatic Surgery, Digestive and Vascular Surgical Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, China

Ma et al.: Mechanism of Calycosin in Pancreatic Cancer by Repressing Circ\_0000285

Recent studies have shown that calycosin possess multiple pharmacological properties, containing anti-cancer activity. Hence, this project explored the effect and possible mechanism of calycosin in pancreatic cancer. After being cultured, SW1990 cells were exposed to different concentrations of calycosin. 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide, plate colony formation, and transwell experiments assessed cell proliferation, colony formation, migration, and invasion. Circ\_0000285 expression was assessed using quantitative reverse transcription-polymerase chain reaction experiment. E-cadherin and N-cadherin protein levels were examined using Western blot. After calycosin treatment, SW1990 cell proliferation, migration, invasion, circ\_0000285 expression, N-cadherin were repressed, and E-cadherin was increased in dose-dependent way. Circ\_0000285 deficiency might hinder cell proliferation, migration, and invasion. Furthermore, the upregulation of circ\_0000285 might partly antagonize calycosin-mediated SW1990 cell proliferation, migration, and invasion inhibition. Calycosin treatment might block pancreatic cancer cell development through down-regulating circ\_0000285.

Key words: Pancreatic cancer, calycosin, circ\_0000285, cell proliferation, migration, invasion

As a highly fatal malignancy of the digestive system, pancreatic cancer is often diagnosed at an advance stage or even metastasis, owning to its highly aggressive nature and atypical early symptoms<sup>[1,2]</sup>. Significant advances in conventional treatments, containing surgical resection, radiotherapy, and chemotherapy, have recently obtained some benefits, but the long-term survival is still poor<sup>[3]</sup>. During recent years, some Traditional Chinese Medicines (TMCs) possessed anti-oxidative stress and anti-tumor effects for alleviating the progression and development in different human cancers, including pancreatic cancer<sup>[4,5]</sup>. As a functional phytoestrogen isoflavone isolated from TCM radix Astragalus, Calycosin (CC) is evidenced with diverse pharmacological properties, such as cytoprotection, anti-oxidative, and hypoglycemic effects<sup>[6]</sup>. Beneficially, CC has demonstrated favorable anti-tumor properties in a variety of malignancies via different signal pathways<sup>[7,8]</sup>. However, the influence of CC on the biological behavior of pancreatic cancer cells is unclear. Interestingly, some laboratory work have suggested the repression of CC on human cancer cell growth and metastasis by regulating noncoding Ribonucleic Acid (RNA), such as lncRNA HOTAIR and microRNA (miR)-375<sup>[9,10]</sup>. Unlike other non-coding RNAs, circular RNAs (circRNAs) have covalently closed loop structure produced by the back-spliced mechanism of pre-messenger RNA (mRNA), which are abnormally expressed in numerous tumors and partake in the process of tumorigenesis and development<sup>[11]</sup>. Previous studies have indicated that circ 0000285 acted as a well-known carcinogenic factor in various human cancers<sup>[12,13]</sup>, but its role in pancreatic cancer has not been reported. Accordingly, this project focused on whether CC might control pancreatic cancer progression via modulating circ 0000285.

Accepted 04 March 2024 Revised 24 August 2023 Received 15 January 2023 Indian J Pharm Sci 2024;86(2):442-447

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms

## **MATERIALS AND METHODS**

# Reagents:

CC (purity >98 %; Biopurify, Chengdu, China) was dissolved in Dimethyl Sulfoxide (DMSO). Human pancreatic cancer cells (SW1990 cells; American Type Culture Collection (ATCC), Manassas, Virginia, United States of America (USA)) were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Beyotime, Shanghai, China) containing 10 % Fetal Bovine Serum (FBS). Trizol reagent and Lipofectamine<sup>™</sup> 3000 transfection reagent were provided by Invitrogen (Carlsbad, California, USA). Tiangen (Beijing, China) supplied reverse transcription and fluorescent quantitative Polymerase Chain Reaction (qPCR) reagents RiboBio (Guangzhou, China) and Genomeditech (Shanghai, China) respectively offered si-circ 0000285 and control (si-NC), and plasmid cloning Deoxyribonucleic Acid (pcDNA)-circ 0000285 and its control (pcDNA). Transwell chamber and Matrigel® were supplied by Solarbio (Beijing, China). Rabbit antihuman E-cadherin, N-cadherin, internal reference Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH), and secondary antibodies were acquired from Cell Signaling Technology (CST) (Danvers, Massachusetts, USA).

# Method:

Cell treatment: In this research, SW1990 cells in 6-well plates were respectively treated with  $5 \mu mol/l$ , 10  $\mu mol/l$ , and 20  $\mu mol/l$  CC for 24  $h^{[14]}$ , marked CC-Low (L), CC-Medium (M), and CC-High (H) group. At the same time, normal cultured SW1990 cells acted as control group. Based on Lipofectamine method, we knockdowned circ\_0000285 by transfecting si-NC or si-circ\_0000285 into SW1990 cells. In addition, pcDNA or pcDNA-circ\_0000285 was transfected into SW1990 cells, followed by incubation with 20  $\mu mol/l$  CC for 24 h, recorded as CC+pcDNA and CC+pcDNA-circ\_0000285 group.

3-(4,5-Dimethyl-2-Thiazolyl)-2,5-Diphenyl-2-H-Tetrazolium Bromide (MTT) assay: In 96-well plates, collected SW1990 cells ( $2 \times 10^3$ ) were mixed with 20 µl MTT solution at 37°. After continuing to incubate for 4 h, discard the supernatant, each well were incubated with 150 µl DMSO, followed by culture for 5 min avoiding light. Lastly, an enzyme labeling instrument at 490 nm was implemented for Absorbance value (A value). Clone formation assay: In 6-well plates, 1000 SW1990 cells were cultured for about 2 w. After Phosphate Buffer Solution (PBS) washing, cells were subjected to 4 % paraformaldehyde fixture for 15 min and crystal violet staining for 5 min. Finally, the number of cell clone formation was assessed using a microscope ( $\geq$ 50 cells were regarded as a colony).

**Transwell assay:** For migration experiment,  $5 \times 10^4$  SW1990 cells in serum-free medium were added to upper chamber, and bottom counterpart was charged with 600 µl medium with 10 % FBS. Then, the cells were continued for 24 h. After staining for 10 min, a microscope was applied for the analysis of migrated cell number. For invasion,  $2 \times 10^5$  cells were added to upper chamber, which was pre-spread with Matrigel<sup>®</sup> matrix gel dilution (40 µl/well). Subsequent steps were similar to the cell migration experiment.

**qRT-PCR assay:** After 1 ml Trizol reagent treatment, total RNAs from SW1990 cells were prepared, followed by synthesizing complementary DNA (cDNA) using reverse transcription kit. Subsequently, qRT-PCR amplification reaction was carried out using the template cDNA. Finally, the data from each group was analyzed using Roche LightCycler<sup>®</sup> 480 fluorescence quantitative PCR.

Western blot assay: According to 400  $\mu$ l Radioimmunoprecipitation Assay (RIPA) lysate, total SW1990 cell proteins were extracted. After Bicinchoninic Acid Assay (BCA) method determination, protein samples were taken for Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). Following shifted onto membranes, primary antibodies; E-cadherin (1:1000), N-cadherin (1:1000), and GAPDH (1:2000) were labeled at 4° for 24 h. After soaking in the secondary antibody (1:5000) dilution for 2 h, each band was analyzed.

# Statistical analysis:

In this research, the data was analyzed using Statistical Package for the Social Sciences (SPSS) 21.0 and displayed as  $(\bar{x}\pm s)$ . Data comparison was made by Student's t-test or one-way Analysis of Variance (ANOVA). Difference was deemed statistically significant at p<0.05.

# **RESULTS AND DISCUSSION**

As shown in Table 1, CC treatment might improve

cell proliferation inhibition rates in a dosedependent way, and reduced the number of colony formation, migration, and invasion. Based on the results presented in Table 2, circ\_0000285 expression was gradually decreased in SW1990 cells with increasing concentrations of CC.

Data from Table 3 displayed that circ\_0000285 expression clearly declined after si-circ\_0000285 introduction, and circ\_0000285 level was significantly enhanced by pcDNA circ\_0000285 transfection.

As exhibited in Table 4, circ\_0000285 absence might augment cell proliferation inhibition rates, and constrain cell colony formation, migration, and invasion.

Relative to the CC+pcDNA group, proliferation inhibition rates were suppressed in the CC+pcDNAcirc\_0000285 group, and the numbers of colony formation, migration, invasion were increased as shown in Table 5.

According to the results displayed in fig. 1 and Table 6, CC exposure might enhance E-cadherin and reduce N-cadherin expression in a dosedependent manner. Circ\_0000285 silencing might elevate E-cadherin expression and decrease N-cadherin level. In addition, the overexpression of circ\_0000285 might restrain E-cadherin content and increase N-cadherin expression in CC-treated SW1990 cells.

TABLE 1: INFLUENCES OF CC ON SW1990 CELL DEVELOPMENT	(ā±s.	n=9)
	(^,	

Crown	-		Cell number	
Group Inhibition rate % —	Colony	Migration	Invasion	
Control	0.00±0.00	120.89±7.58	188.56±6.57	148.11±7.56
CC-L	13.53±0.85*	95.33±4.16*	153.44±4.95*	114.22±6.11*
CC-M	25.60±2.04*#	75.44±2.87*#	116.67±5.62*#	84.89±2.96*#
CC-H	43.11±1.20*#&	48.67±3.77*#&	84.89±2.88*# <sup>#</sup>	58.78±4.29*#8
F	1908.961	346.382	675.342	437.497
р	0.000	0.000	0.000	0.000

Note: \*p<0.05 vs. control, #p<0.05 vs. CC-L, and #p<0.05 vs. CC-M

## TABLE 2: EFFECTS OF CC ON circ\_0000285 CONTENT IN SW1990 CELLS

Group	circ_0000285
Control	1.00±0.00
CC-L	0.77±0.05*
CC-M	0.41±0.03*
CC-H	0.14±0.01*# <sup>#</sup>
F	491.003
р	0.000

Note: \*p<0.05 vs. control, #p<0.05 vs. CC-L, and  $^{\mbox{\tiny $t$}}p{<}0.05$  vs. CC-M

## TABLE 3: DETECTION OF circ\_0000285 EXPRESSION

Group	circ_0000285
si-NC	1.00±0.00
si-circ_0000285	0.36±0.03*
t	64.000
p	0.000
pcDNA	1.00±0.00
pcDNA-circ_0000285	3.22±0.14#
t	47.571
р	0.000

Note: \*p<0.05 vs. si-NC and #p<0.05 vs. pcDNA

#### www.ijpsonline.com

## TABLE 4: EFFECTS OF circ\_0000285 SILENCING ON SW1990 CELL GROWTH AND METASTASIS

6	lahihitian rata 0/		Cell number	
Group	Inhibition rate % –	Colony	Migration	Invasion
si-NC	0.00±0.00	124.44±7.63	182.22±7.39	145.44±12.14
si-circ_0000285	35.61±1.73*	61.00±3.74*	98.67±5.06*	70.78±4.05*
t	61.751	22.398	27.986	17.502
р	0.000	0.000	0.000	0.000

Note: \*p<0.05 vs. si-NC group

### TABLE 5: circ\_0000285 MIGHT ABOLISH THE REPRESSION OF CC ON CELL MALIGNANT BEHAVIORS

Crown	Inhibition rate %	Cell number		
Group	Inhibition rate % -	Colony	Migration	Invasion
CC+pcDNA	42.90±2.69	49.67±2.83	85.22±3.85	57.78±4.08
CC+pcDNA-circ_0000285	15.29±0.84*	87.89±4.58*	136.44±6.09*	97.56±5.68*
t	29.392	21.297	21.327	17.064
р	0.000	0.000	0.000	0.000

Note: \*p<0.05 vs. CC+pcDNA group



Fig. 1: Measurement of E-cadherin and N-cadherin protein levels, (1): Control; (2): CC-L; (3); CC-M; (4); CC-H; (5): si-NC; (6); si-circ\_0000285; (7): CC+pcDNA and (8): CC+pcDNA-circ\_0000285

#### TABLE 6: WESTERN BLOT ANALYSIS OF E-CADHERIN AND N-CADHERIN EXPRESSION

Group	E-cadherin	N-cadherin
Control	0.21±0.02	0.60±0.05
CC-L	0.37±0.03*	0.45±0.04*
CC-M	0.53±0.05*#	0.33±0.03*#
CC-H	0.75±0.05*# <sup>®</sup>	0.18±0.02*# <sup>#</sup>
F	303.810	212.000
р	0.000	0.000
si-NC	0.20±0.02	0.62±0.05
si-circ_0000285	$0.58\pm0.06^{\Delta}$	0.23±0.02 <sup>△</sup>
t	18.025	21.726
р	0.000	0.000
CC+pcDNA	0.73±0.05	0.19±0.03
CC+pcDNA-circ_0000285	0.39±0.05	0.41±0.03 <sup>□</sup>
t	14.425	15.556
р	0.000	0.000

Note: \*p<0.05 vs. control, #p<0.05 vs. CC-L, <sup>®</sup>p<0.05 vs. CC-M, <sup>△</sup>p<0.05 vs. si-NC, and <sup>□</sup>p<0.05, vs. CC+pcDNA

Currently, increasing attention has been paid to the active ingredients extracted from TCM that possess anti-tumor effects on pancreatic cancer *via* regulating the differential gene expression<sup>[15]</sup>. Of note, convincing evidence have indicated that dysregulation of circRNA might participate in the process of pancreatic cancer *via* sponging miRNAs<sup>[16,17]</sup>. Nevertheless, it has not been elucidated whether circRNA can be a potential target for pancreatic cancer treatment with TCM.

In recent years, numerous literatures presented the many pharmacological properties of CC, in particular the significant antitumor effects on various types of cancer cells. For example, CC treatment might diminish breast cancer cell invasion via reducing Epithelial-Mesenchymal Transition (EMT)<sup>[18]</sup>. Apart from that, CC addition might hinder cervical cancer cell proliferation and induce apoptosis through increasing miR-375<sup>[10]</sup>. Yet, the research related to CC treatment and pancreatic cancer has not been reported. In this work, SW1990 cell proliferation inhibition rate was improved and colony formation number was reduced after CC treatment, implying the repression of CC on cell proliferative ability. The absence of the epithelial cell marker E-cadherin and the upregulation of the expression of the mesenchymal cell marker N-cadherin are considered to be characteristic of EMT, which exert a key impact in the early stages of cancer cell metastasis<sup>[19]</sup>. Herein, the present work verified that CC exposure might decrease migration and invasion numbers, reduced N-cadherin protein expression, and reinforce E-cadherin content, suggesting that CC treatment might repress tumor cell migration and invasion via inhibition of EMT transformation.

Circ 0000285 was highly expressed in osteosarcoma cells and could promote osteosarcoma cell growth via regulating miR-409-3p/IGFBP3 expression<sup>[20]</sup>. Furthermore, circ\_0000285 promotes laryngeal cancer cell growth and invasion via activating the Wnt/β-catenin pathway<sup>[21]</sup>. Consistent with these reports, our data confirmed that circ 0000285 knockdown might impede SW1990 cell proliferation, migration, and invasion. Of interest, our data displayed that circ 0000285 content was clearly reduced in CC-induced SW1990 cells, and its overexpression might partly abolish the suppression of CC on SW1990 cell malignant behaviors. This observation indicated that applying CC was able to dampen SW1990 cell growth and metastasis by decreasing circ\_0000285 expression. In summary, CC treatment repress pancreatic cancer cell malignant behaviors through modulating circ\_0000285. These results suggested that circ\_0000285 may be a potential target for tumor treatment with CC, laying an experimental foundation for further revealing the molecular mechanism of CC against pancreatic cancer. However, its specific mechanism of action still needs to be further investigated.

## **Conflict of interests:**

The authors declared no conflict of interests.

### REFERENCES

- 1. Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, *et al.* Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett 2021;520:1-11.
- Halbrook CJ, Lyssiotis CA, di Magliano MP, Maitra A. Pancreatic cancer: Advances and challenges. Cell 2023;186(8):1729-54.
- Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: A review of current treatment and novel therapies. J Invest Surg 2023;36(1):2129884.
- 4. Zhang Y, Xu H, Li Y, Sun Y, Peng X. Advances in the treatment of pancreatic cancer with traditional Chinese medicine. Front Pharmacol 2023;14:1089245.
- 5. Gao Y, Chen S, Sun J. Traditional Chinese medicine may be further explored as candidate drugs for pancreatic cancer: A review. Phytother Res 2021;35(2):603-28.
- Deng M, Chen H, Long J, Song J, Xie L, Li X. Calycosin: A review of its pharmacological effects and application prospects. Expert Rev Anti Infect Ther 2021;19(7):911-25.
- Zhu L, Liu S, Liao YF, Sheng YM, He JC, Cai ZX, *et al.* Calycosin suppresses colorectal cancer progression by targeting ERβ, upregulating PTEN, and inhibiting PI3K/Akt signal pathway. Cell Biol Int 2022;46(9):1367-77.
- Zhang Y, Zhang JQ, Zhang T, Xue H, Zuo WB, Li YN, *et al.* Calycosin induces gastric cancer cell apoptosis *via* the ROSmediated MAPK/STAT3/NF-κB pathway. Onco Targets Ther 2021;14:2505-17.
- 9. Li Y, Miao H, Wei W, Tian J, Chen J. Inhibitory effect of calycosin on breast cancer cell progression through downregulating lncRNA HOTAIR and downstream targets: HuR and IGF2BP1. Acta Biochim Biophys Sin 2022;55(2):225-36.
- Zhang D, Sun G, Peng L. Calycosin inhibits viability, induces apoptosis, and suppresses invasion of cervical cancer cells by upregulating tumor suppressor miR-375. Arch Biochem Biophys 2020;691:108478.
- Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol 2022;19(3):188-206.
- 12. Zhang B, Li Q, Song Z, Ren L, Gu Y, Feng C, *et al.* Hsa\_circ\_0000285 facilitates thyroid cancer progression by regulating miR-127-5p/CDH2. J Clin Lab Anal 2022;36(7):e24421.
- 13. Zeng Q, Ji X, Li X, Tian Y. Circ\_0000285 regulates

nasopharyngeal carcinoma progression through miR-1278/ FNDC3B axis. Hum Exp Toxicol 2023;42:9603271221141689.

- 14. Wang W, Zhang LY, Zhao ZL. Study on the mechanism of calycosin inhibiting glioma cell proliferation. J Shenyang Pharm Univ 2020;37(8):725-9.
- Zhang Y, Zhang XX, Yuan RY, Ren T, Shao ZY, Wang HF, et al. Cordycepin induces apoptosis in human pancreatic cancer cells via the mitochondrial-mediated intrinsic pathway and suppresses tumor growth *in vivo*. Onco Targets Ther 2018;11(1):4479-90.
- Li L, Wang N, Wang J, Li J. Hsa\_circRNA\_001859 regulates pancreatic cancer progression and epithelial-mesenchymal transition through the miR-21-5p/SLC38A2 pathway. Cancer Biomark 2023;37(1):39-52.
- Hou YS, Li X. Circ\_0005273 induces the aggravation of pancreatic cancer by targeting KLF12. Eur Rev Med Pharmacol

Sci 2020;24(22):11578-86.

- Zhang Z, Lin M, Wang J, Yang F, Yang P, Liu Y, *et al.* Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT *via* BATF/TGF-beta1. Aging (Albany NY) 2021;13(12):16009-23.
- de Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13(2):97-110.
- 20. Long Z, Gong F, Li Y, Fan Z, Li J. Circ\_0000285 regulates proliferation, migration, invasion and apoptosis of osteosarcoma by miR-409-3p/IGFBP3 axis. Cancer Cell Int 2020;20(1):481-91.
- Qin JB, Chang W, Yuan GH, Huang L, Qiu ZF. Circular RNA hsa\_circ\_0000285 acts as an oncogene in laryngocarcinoma by inducing Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci 2020;24(19):9773-83.